Serina completes Cohort 1 dosing in SER-252 Parkinson's trial ahead of schedule

Serina Therapeutics reported second-quarter 2026 results on August 13, 2026, along with several pipeline updates. Following completion of sentinel dosing and a recommendation from the independent Safety Monitoring Committee to continue, Serina finished enrolling and dosing all eight patients in Cohort 1 of its Phase 1b registrational study of SER-252 in July 2026.¹ The company said this milestone came ahead of its previously disclosed guidance of the end of the third quarter of 2026.¹

Under the study protocol, the independent Safety Monitoring Committee will conduct a blinded review of Cohort 1's safety and tolerability data to guide the decision on whether to proceed with dose escalation.¹ Serina said top-line data from the single-ascending-dose portion of the study remain targeted for the first half of 2027.¹

The trial itself is structured as a randomized, double-blind, placebo-controlled Phase 1b study with a single-ascending-dose portion enrolling five cohorts of eight patients (40 total) and a multiple-ascending-dose portion enrolling up to three cohorts of sixteen patients (48 total), in adults with Parkinson's disease and motor fluctuations.¹

On the partnership side, Serina said that in June 2026 it entered a collaboration with Gannet BioChem covering process development, scale-up, and manufacturing work for SER-252.¹ Separately, in July 2026 the company appointed Farrell Simon, Pharm.D., to its Board of Directors, including its Audit and Compensation Committees.¹

On finances, Serina reported cash and cash equivalents of $23.0 million as of June 30, 2026.¹ The company did not include a specific cash runway statement in this release's stated updates beyond that cash balance.